全球乳房復發評分測試市場

預計到 2030 年，全球乳房復發評分測試市場規模將達到 4.141 億美元

全球乳癌復發評分測試市場規模預計在2024年為2.49億美元，到2030年將達到4.141億美元，在分析期間（2024-2030年）的複合年成長率為8.8%。本報告分析的乳癌細分領域之一—1期乳癌，預計其複合年成長率為10.3%，到分析期結束時規模將達到1.584億美元。 2期乳癌細分領域在分析期間的複合年成長率預計為9.5%。

美國市場規模估計為 6,790 萬美元，而中國市場預計複合年成長率為 13.9%

美國乳癌復發評分檢測市場規模預計在2024年達到6,790萬美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到9,150萬美元，在2024-2030年的分析期間內，複合年成長率為13.9%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為4.4%和8.5%。在歐洲，預計德國市場的複合年成長率為5.9%。

全球乳房復發評分測試市場－主要趨勢與促進因素摘要

基因組分析將如何徹底改變乳癌的預後和治療計畫？

乳房復發評分測試與 Oncotype DX 等基因組檢測結合使用，大大改變了臨床醫生評估乳癌復發風險和做出有關輔助性治療的重要決策的方式。該測試評估特定癌症相關基因組（通常為 21 個基因）的表達，以創建個人化復發評分，該評分可估計初次治療後 10 年內遠處癌症復發的可能性。與嚴重依賴臨床和病理特徵（例如腫瘤大小、淋巴結轉移和荷爾蒙受體狀態）的傳統預後工具不同，乳腺復發評分測試提供了腫瘤生物學的分子洞察。這使腫瘤學家能夠將患者分為低風險、中風險和高風險類別，並相應地制定治療計劃。例如，復發評分低的患者通常可以放棄化療，避免嚴重的副作用而不會影響存活結果。這是乳癌治療的一個重要模式轉移，朝著精準腫瘤學邁進，強調個人化治療而不是一刀切的方案。 TAILORx 和 RxPONDER 等里程碑式臨床試驗所累積的臨床證據已檢驗該檢測的臨床效用，並增強了醫生和患者對其結果的信心。隨著此檢測效用的認可度不斷提高，它擴大被納入早期荷爾蒙受體陽性、HER2陰性乳癌的標準治療方案中，從而改善了臨床療效，並提高了患者滿意度和生活品質。這項檢測也順應了價值導向醫療的轉變，能夠制定更具成本效益的治療方案，並減少不必要的治療性介入。

臨床指引和報銷政策發揮什麼作用？

乳房復發評分測試日益被納入臨床指南和報銷框架，這對加速該測試在全球的普及起到了關鍵作用。美國臨床腫瘤學會 (ASCO)、美國國家綜合癌症網路 (NCCN) 和聖加侖國際專家共識等權威組織已將該測試納入激素受體陽性、HER2 陰性乳癌的正式管理指南。這些認可賦予了該測試強大的臨床可信度，並鼓勵世界各地的腫瘤學家將其作為常規診斷工具。同時，許多公共和私人保險公司，尤其是美國、加拿大和一些歐洲國家的保險公司，都核准了該測試的報銷，承認其在改善患者預後和減少過度治療方面的長期價值。報銷政策對測試利用率有直接影響，核准的診斷測試很可能會被廣泛採用，尤其是在醫療保健系統集中的國家。此外，保險覆蓋範圍的擴大也方便了醫療資源匱乏的人群接受檢測，使精準腫瘤學更加公平。經濟評估顯示，該檢測可以顯著節省不必要的化療、住院治療和治療相關副作用的長期管理費用，從而指南政策決策。在新興市場，隨著當地監管機構對臨床數據和成本效益報告的評估，將此類基因組檢測納入公共衛生策略的進程緩慢但穩定。此外，製藥和診斷公司正在積極與衛生署和付款方合作，以建立檢測採用的途徑。醫療需求、政策支持和成本控制目標的整合鞏固了乳癌復發評分測試在現代癌症治療中的地位。

技術進步是否提高了測試的準確性和全球可近性？

分子診斷技術的進步極大地提高了乳房復發評分測試的準確性、擴充性和可及性。該測試最初僅在中心實驗室進行，且週轉時間較長，而新版本得益於簡化的檢體處理、更快的基因表現分析和更強大的演算法，可確保準確計算復發風險。 RNA 萃取技術和即時PCR平台的改進使得即使少量切片檢查樣本也能獲得可重複的結果，使該測試在臨床環境中更加通用。技術創新也擴展了可用的檢體類型，包括芯針活體組織切片和福馬林固定石蠟包埋組織，進一步簡化了測試管理的物流。隨著基因組資料庫的增加和機器學習被納入腫瘤學研究，未來對復發評分的增強可能還會納入其他數據，例如患者人口統計數據、合併症和免疫特徵，以實現更個人化的風險評估。在可近性方面，診斷開發公司與區域病理實驗室之間的夥伴關係正在實現分散式檢查模式。數位病理學和雲端基礎的數據傳輸系統也促進了遠距會診和同行評審，彌合了都市區癌症中心之間的差距。檢測設備的小型化和自動化基因組分析的出現，使得規模較小的醫療機構能夠提供高精度的檢測。總而言之，這些技術創新將在確保不同患者群體檢測結果的一致性以及在全球範圍內擴大檢測覆蓋範圍方面發揮關鍵作用。

推動全球乳癌復發評分測試擴展的關鍵市場因素有哪些？

乳癌復發評分測試市場的成長受到多種因素的推動，這些因素與癌症治療通訊協定的改變、技術的成熟度以及患者期望的轉變直接相關。其中一個關鍵促進因素是全球乳癌發生率的上升，這正在迅速提高人們的認知度和早期診斷水平，尤其是在年輕人口和開發中地區。這催生了對能夠個人化治療並避免過度治療帶來的身心和經濟負擔的工具的強烈需求。同時，早期乳癌逐漸轉向以化療為重點的逐漸減量治療，使得復發評分測試成為關鍵的決策輔助工具。醫療保健提供者擴大尋求檢驗。此外，越來越多知情的患者群體要求治療的透明度和精準性，這促使腫瘤學家將基因組檢測作為標準治療，而不僅僅是一項建議。在醫療服務提供者方面，多學科腫瘤委員會和基於價值的醫療保健模式正在進一步推動檢測的利用，以最佳化資源利用率和療效。另一個關鍵的市場力量是診斷公司積極地透過策略夥伴關係、宣傳宣傳活動和臨床醫生教育計畫擴大其全球影響力。這些努力正在產生重大影響，尤其是在亞太和拉丁美洲地區，這些地區的本地檢驗研究和監管核准正在蓬勃發展。最後，將基因組學整合到常規癌症治療（從生物標記引導治療到風險分層）的更廣泛動力，為復發評分檢測的持續成長創造了肥沃的環境。這些相互關聯的因素，包括流行病學、臨床、經濟和技術因素，共同推動了全球乳房復發評分檢測市場保持強勁的上升趨勢。

部分

適應症（1期乳癌適應症、2期乳癌適應症、雌激素受體陽性癌症適應症、淋巴結陰性癌症適應症）、最終用戶（醫院最終用戶、專科癌症中心最終用戶、其他最終用戶）

受訪公司範例

• Abbott Laboratories
• Agendia
• Biocartis
• Bio-Rad Laboratories
• Caris Life Sciences
• Epic Sciences
• Exact Sciences
• Foundation Medicine
• Guardant Health
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics
• NanoString Technologies
• Natera
• OncoDNA
• Oncomatryx
• Qiagen
• Roche Diagnostics
• Thermo Fisher Scientific
• Varian Medical Systems

人工智慧整合

我們正在利用可操作的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業SLM 的典型規範，而是建立了一個從全球專家收集的內容庫，其中包括視訊錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口狀況（成品和原始OEM）預測其競爭態勢的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括銷貨成本成本 (COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 比賽

Global Breast Recurrence Score Test Market to Reach US$414.1 Million by 2030

The global market for Breast Recurrence Score Test estimated at US$249.0 Million in the year 2024, is expected to reach US$414.1 Million by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Stage 1 Breast Cancer Indication, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$158.4 Million by the end of the analysis period. Growth in the Stage 2 Breast Cancer Indication segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$67.9 Million While China is Forecast to Grow at 13.9% CAGR

The Breast Recurrence Score Test market in the U.S. is estimated at US$67.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$91.5 Million by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Breast Recurrence Score Test Market - Key Trends & Drivers Summarized

How Is Genomic Profiling Revolutionizing Breast Cancer Prognosis and Treatment Planning?

The Breast Recurrence Score Test, most commonly associated with genomic assays like Oncotype DX, has dramatically transformed how clinicians assess the risk of breast cancer recurrence and make critical decisions about adjuvant therapy. This test evaluates the expression of a specific panel of cancer-related genes-typically 21 genes-to produce a personalized recurrence score that estimates the likelihood of distant cancer recurrence within ten years of initial treatment. Unlike traditional prognostic tools that rely heavily on clinical and pathological features such as tumor size, lymph node involvement, and hormone receptor status, the Breast Recurrence Score Test provides a molecular-level insight into tumor biology. This enables oncologists to better stratify patients into low, intermediate, or high-risk categories, tailoring treatment plans accordingly. For example, patients with a low recurrence score can often forgo chemotherapy, thus avoiding its considerable side effects without compromising survival outcomes. This has marked a significant paradigm shift in breast cancer care, moving toward precision oncology that emphasizes individualized treatment over one-size-fits-all protocols. The growing body of clinical evidence from landmark trials such as TAILORx and RxPONDER has validated the clinical utility of the test, boosting physician and patient confidence in its results. As awareness of the test’s capabilities grows, it is increasingly being integrated into standard care protocols for early-stage, hormone receptor-positive, HER2-negative breast cancer. The result is not just improved clinical outcomes, but enhanced patient satisfaction and quality of life. The test also aligns with the shift toward value-based healthcare, by enabling more cost-effective treatment planning and reducing unnecessary therapeutic interventions.

What Role Are Clinical Guidelines and Reimbursement Policies Playing in Driving Adoption?

The increasing integration of the Breast Recurrence Score Test into clinical guidelines and insurance reimbursement frameworks has played a critical role in accelerating its global adoption. Esteemed bodies such as the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), and the St. Gallen International Expert Consensus have incorporated the test into their formal guidelines for managing hormone receptor-positive, HER2-negative breast cancer. These endorsements have lent strong clinical credibility to the test, encouraging oncologists across the globe to adopt it as a routine diagnostic tool. In tandem, many public and private insurers-particularly in the U.S., Canada, and parts of Europe-have approved reimbursement for the test, recognizing its long-term value in improving patient outcomes and minimizing overtreatment. Reimbursement policies have a direct influence on test utilization, especially in countries with centralized healthcare systems, where approved diagnostic tests are more likely to be widely adopted. Moreover, expanding insurance coverage has facilitated access to the test for underserved populations, making precision oncology more equitable. Policy decisions have also been guided by economic evaluations that show the test can significantly reduce the costs associated with unnecessary chemotherapy, hospital stays, and long-term management of treatment-related side effects. In emerging markets, the inclusion of such genomic assays in public health strategies is slower but steadily increasing, as local regulatory bodies assess clinical data and cost-effectiveness reports. Additionally, pharmaceutical companies and diagnostic firms are actively engaging with health ministries and payers to establish pathways for test adoption. The alignment of medical necessity, policy support, and cost-containment objectives has solidified the Breast Recurrence Score Test’s place in contemporary cancer care.

Are Technological Advancements Enhancing Test Accuracy and Global Accessibility?

The evolution of molecular diagnostics technology has greatly enhanced the accuracy, scalability, and accessibility of Breast Recurrence Score Tests. Originally processed only in centralized labs with long turnaround times, newer iterations benefit from streamlined sample processing, faster gene expression analysis, and increasingly robust algorithms that ensure precise recurrence risk calculation. The improvement in RNA extraction techniques and real-time PCR platforms has led to more reproducible results, even from small biopsy samples, thus making the test more versatile across clinical scenarios. Technological innovation has also expanded the range of usable specimen types, including core needle biopsies and formalin-fixed paraffin-embedded tissues, further simplifying the logistics of test administration. As genomic databases grow and machine learning becomes more integrated into oncology research, future enhancements in recurrence scoring may also incorporate additional data such as patient demographics, comorbidities, and immune profiles for even more individualized risk assessment. In terms of accessibility, partnerships between diagnostic developers and regional pathology labs are enabling decentralized testing models, allowing quicker turnaround times and lowering the barrier to adoption in lower-resource settings. Digital pathology and cloud-based data transfer systems also facilitate remote consultation and peer review, bridging the gap between urban and rural cancer centers. The miniaturization of lab instrumentation and the advent of automated genomic analysis are making it feasible for smaller healthcare facilities to offer these tests with high accuracy. Collectively, these innovations not only ensure consistent performance across patient populations but also play a crucial role in scaling up test availability globally-making personalized breast cancer care a tangible reality for more women, regardless of geographic location.

What Key Market Forces Are Driving the Expansion of Breast Recurrence Score Testing Worldwide?

The growth in the Breast Recurrence Score Test market is driven by several factors directly linked to changing cancer care protocols, technological maturity, and shifting patient expectations. A major driver is the global rise in breast cancer incidence, particularly among younger populations and in developing regions where awareness and early diagnosis are rapidly improving. This has created a strong demand for tools that can personalize treatment and avoid the physical, emotional, and financial toll of overtreatment. Concurrently, the shift toward de-escalation of therapy-especially chemotherapy-in early-stage breast cancer has positioned recurrence score tests as critical decision-making aids. Healthcare providers are increasingly seeking diagnostic tools that provide actionable insights, and the Breast Recurrence Score Test fits that role by delivering clinically validated, easy-to-interpret results that directly influence treatment pathways. Moreover, a growing population of well-informed patients is demanding transparency and precision in their care, leading oncologists to adopt genomic testing not just as a recommendation, but as a standard of care. On the provider side, multi-disciplinary tumor boards and value-based healthcare models are further promoting test usage to optimize resource utilization and outcomes. Another important market force is the active role of diagnostic companies in expanding their global footprint through strategic partnerships, awareness campaigns, and clinician education programs. These efforts are particularly impactful in Asia-Pacific and Latin American regions, where local validation studies and regulatory approvals are gaining momentum. Finally, the broader movement toward integrating genomics into routine oncology practice-from biomarker-based treatment to risk stratification-has created a fertile environment for the sustained growth of recurrence score testing. These interconnected factors-epidemiological, clinical, economic, and technological-are collectively ensuring that the global market for Breast Recurrence Score Tests remains on a robust upward trajectory.

SCOPE OF STUDY:

The report analyzes the Breast Recurrence Score Test market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication, Lymph-Node-Negative Cancer Indication); End-Use (Hospitals End-Use, Specialty Cancer Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Agendia
• Biocartis
• Bio-Rad Laboratories
• Caris Life Sciences
• Epic Sciences
• Exact Sciences
• Foundation Medicine
• Guardant Health
• Hologic Inc.
• Illumina Inc.
• Myriad Genetics
• NanoString Technologies
• Natera
• OncoDNA
• Oncomatryx
• Qiagen
• Roche Diagnostics
• Thermo Fisher Scientific
• Varian Medical Systems

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Breast Recurrence Score Test - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Precision Oncology Throws the Spotlight on Breast Recurrence Score Tests as Prognostic Tools
  • Shift Toward Personalized Breast Cancer Treatment Spurs Growth in Genomic Recurrence Risk Testing
  • Here's How Clinical Guidelines Are Driving Adoption of Recurrence Score Tests to Inform Chemotherapy Decisions
  • Expanding Use in Early-Stage HR-Positive, HER2-Negative Breast Cancer Strengthens the Business Case for Risk Stratification
  • Increased Physician and Patient Awareness Fuels Demand for Evidence-Based, Genomic-Driven Treatment Planning
  • Here's the Story: How TAILORx and RxPONDER Trial Results Are Validating Clinical Utility Across Demographics
  • Integration with Electronic Health Records and Oncology Decision Support Systems Enhances Workflow Efficiency
  • Growing Emphasis on Avoiding Overtreatment Supports the Economic Value Proposition of Recurrence Score Testing
  • Global Expansion of Molecular Pathology Labs Enables Broader Access in Developed and Emerging Markets
  • Rising Incidence of Breast Cancer Worldwide Expands the Addressable Market for Genomic Recurrence Assays
  • Innovation in Liquid Biopsy and Multi-Gene Panels May Disrupt or Complement Current Recurrence Score Test Models
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Breast Recurrence Score Test Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Breast Recurrence Score Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Stage 1 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Stage 1 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Stage 2 Breast Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Stage 2 Breast Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Estrogen-Receptor-Positive Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Lymph-Node-Negative Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Lymph-Node-Negative Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Specialty Cancer Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Specialty Cancer Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: China 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: China 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Breast Recurrence Score Test by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: France 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: France 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Breast Recurrence Score Test by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 113: Australia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Australia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Australia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 116: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: India 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 119: India Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: India Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: India 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 125: South Korea Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: South Korea Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: South Korea 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Asia-Pacific Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Breast Recurrence Score Test by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 146: Argentina Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Argentina Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Argentina 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 152: Brazil Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Brazil Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Brazil 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 158: Mexico Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Mexico Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Mexico 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Latin America Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Rest of Latin America 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Breast Recurrence Score Test by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Breast Recurrence Score Test by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 179: Iran Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Iran Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Iran 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 185: Israel Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Israel Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Israel 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Saudi Arabia Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Saudi Arabia 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 197: UAE Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: UAE Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: UAE 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Middle East Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Middle East 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Breast Recurrence Score Test Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Breast Recurrence Score Test by Indication - Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Breast Recurrence Score Test by Indication - Percentage Breakdown of Value Sales for Stage 1 Breast Cancer Indication, Stage 2 Breast Cancer Indication, Estrogen-Receptor-Positive Cancer Indication and Lymph-Node-Negative Cancer Indication for the Years 2014, 2025 & 2030
  • TABLE 209: Africa Recent Past, Current & Future Analysis for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Africa Historic Review for Breast Recurrence Score Test by End-Use - Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Africa 16-Year Perspective for Breast Recurrence Score Test by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Specialty Cancer Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION